PL3407910T3 - Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni - Google Patents
Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koniInfo
- Publication number
- PL3407910T3 PL3407910T3 PL17702827.1T PL17702827T PL3407910T3 PL 3407910 T3 PL3407910 T3 PL 3407910T3 PL 17702827 T PL17702827 T PL 17702827T PL 3407910 T3 PL3407910 T3 PL 3407910T3
- Authority
- PL
- Poland
- Prior art keywords
- mva
- equine encephalitis
- modified vaccinia
- recombinant modified
- ankara
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12141—Use of virus, viral particle or viral elements as a vector
- C12N2720/12143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16153394 | 2016-01-29 | ||
| EP16157055 | 2016-02-24 | ||
| EP16185012 | 2016-08-19 | ||
| PCT/EP2017/051807 WO2017129765A1 (en) | 2016-01-29 | 2017-01-27 | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3407910T3 true PL3407910T3 (pl) | 2022-08-16 |
Family
ID=57960428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17702827.1T PL3407910T3 (pl) | 2016-01-29 | 2017-01-27 | Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10881725B2 (pl) |
| EP (1) | EP3407910B1 (pl) |
| CA (1) | CA3009928A1 (pl) |
| DK (1) | DK3407910T3 (pl) |
| ES (1) | ES2921605T3 (pl) |
| HU (1) | HUE059343T2 (pl) |
| PL (1) | PL3407910T3 (pl) |
| WO (1) | WO2017129765A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3261669B1 (en) | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CA3009928A1 (en) * | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
| AU2017222687B2 (en) | 2016-02-25 | 2022-02-24 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human Flt3L and use thereof as immuno-therapeutic agents against solid tumors |
| CN116440176A (zh) | 2016-02-25 | 2023-07-18 | 纪念斯隆凯特琳癌症中心 | 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| CA3111273C (en) | 2018-09-06 | 2024-03-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
| CN113717951A (zh) * | 2021-08-05 | 2021-11-30 | 中国科学院武汉病毒研究所 | 一种基于马脑炎病毒的溶瘤病毒及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| EP1064305B1 (en) | 1998-03-27 | 2004-09-15 | The Secretary of State for Defence | Recombinant virus |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| WO2002018585A2 (en) | 2000-08-29 | 2002-03-07 | Wyeth Holdings Corporation | Packaging of positive-strand rna virus replicon particles |
| IL154712A0 (en) | 2000-11-23 | 2003-10-31 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
| US6800289B2 (en) | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| NZ536502A (en) | 2002-05-16 | 2005-10-28 | Bavarian Nordic As | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome for inducing an immune response in a mammal |
| ES2222095B1 (es) | 2003-07-02 | 2005-11-16 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia | Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones. |
| US7998733B2 (en) | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| EP2626078A1 (en) | 2007-02-23 | 2013-08-14 | Her Majesty The Queen, In Right Of Canada, As Represented by the Minister of National Defence | Inoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides |
| WO2010060632A1 (en) | 2008-11-27 | 2010-06-03 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| US9173933B2 (en) | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
| US9555090B2 (en) | 2012-04-04 | 2017-01-31 | The United States of America as repesented by the Secretary of Army, on behalf of the U.S. Army Medical Research Institute of Infections Diseases | Equine encephalitis virus vaccines and methods of using thereof |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| UA118340C2 (uk) | 2012-10-28 | 2019-01-10 | Баваріан Нордік А/С | Промотор pr13.5 для стійких t-клітинних та гуморальних імунних реакцій |
| CA3009928A1 (en) * | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
-
2017
- 2017-01-27 CA CA3009928A patent/CA3009928A1/en active Pending
- 2017-01-27 WO PCT/EP2017/051807 patent/WO2017129765A1/en active Application Filing
- 2017-01-27 DK DK17702827.1T patent/DK3407910T3/da active
- 2017-01-27 HU HUE17702827A patent/HUE059343T2/hu unknown
- 2017-01-27 PL PL17702827.1T patent/PL3407910T3/pl unknown
- 2017-01-27 US US16/073,434 patent/US10881725B2/en active Active
- 2017-01-27 ES ES17702827T patent/ES2921605T3/es active Active
- 2017-01-27 EP EP17702827.1A patent/EP3407910B1/en active Active
-
2021
- 2021-01-04 US US17/140,357 patent/US11571471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2921605T3 (es) | 2022-08-30 |
| HUE059343T2 (hu) | 2022-11-28 |
| US10881725B2 (en) | 2021-01-05 |
| EP3407910B1 (en) | 2022-04-13 |
| EP3407910A1 (en) | 2018-12-05 |
| WO2017129765A1 (en) | 2017-08-03 |
| CA3009928A1 (en) | 2017-08-03 |
| DK3407910T3 (da) | 2022-07-18 |
| US20190038739A1 (en) | 2019-02-07 |
| US11571471B2 (en) | 2023-02-07 |
| US20210205439A1 (en) | 2021-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290052A (en) | Recombinantly modified vaccinia ankara virus filovirus vaccine | |
| PL3407910T3 (pl) | Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni | |
| HK1255847A1 (zh) | 針對乙型肝炎病毒的疫苗 | |
| PL3480307T3 (pl) | Nowy genetycznie zmodyfikowany wirus krowianki | |
| HK1251459A1 (zh) | 使用滅活的非複製型的修飾的痘苗病毒安卡拉(mva)作為實體腫瘤的單一免疫療法或與免疫檢查點阻斷劑的組合 | |
| SG11201900439XA (en) | Recombinant vaccinia virus and use thereof | |
| ZA201801091B (en) | Recombinant orf virus vector | |
| IL254698A0 (en) | A vaccine based on the recombinant Jarl Lin mumps virus 2 | |
| SG11201808268UA (en) | Recombinant hansenula-based high dosage hepatitis b vaccine | |
| HK1251924A1 (zh) | Foxm1衍生的肽和包含它們的疫苗 | |
| PT3407910T (pt) | Vacina contra o vírus da encefalite equina à base de vírus vaccinia ankara modificado (mva) recombinante | |
| EP3211073A4 (en) | Replicative vaccinia virus vector hiv vaccine | |
| GB201615311D0 (en) | Virus, Vaccine cures | |
| HK1251928A1 (zh) | Mphosph1衍生的肽和包括它的疫苗 | |
| GB201706600D0 (en) | Virus preparations | |
| GB201702193D0 (en) | Hepatitis E virus vaccine |